March 21, 2024 7:34am

Emphasizing that there is a reason, what's about to happen has a purpose or a reason

Subscription is coming; a “buck” a day will keep your portfolio in play - be a subscriber to continue reading! Join me … in the NO spin zone and new website!

“On the plus side, even just a few days of sideways action or a mild pullback would let the cell and gene therapy sector catch on and I didn’t say totally catch- up.”

Never leave an investor uninformed!

 

Remember that overnight and pre-open actions’ futures and global markets doesn't necessarily translate into actual trading in the today’s market session.

I answer or qualify the sector’s equity’s movement; with an emphasis on which company is gaining or losing stride in their portfolio for the short-term

I also follow the dictum, quoting Churchill that “short words are best, and the old words when short are best of all.”

 

Thursday: The pre-open Dow futures are UP +0.22% or (+86 points), the S&P futures are UP +0.35% or (+19 points) as the Nasdaq futures are up +0.77% or (+143 points)

Stock futures were positive on Thursday,

European markets opened higher,

Asia Pacific markets closed higher.

 

Henry’omics:

We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies …

Wednesday: The Dow closed UP +401.37 points or +1.03%, the S&P closed UP +46.11 points +0.89% while the Nasdaq closed UP +202.62 points or +1.25%

Reiterating, “The Fed left rates unchanged but said that it plans to cut three times before the end of the year, reaffirming its previous forecast from December. That said, the central bank indicated that it needs greater evidence that inflation is easing before it starts taking its foot off the brakes.” <CNBC>

Economic Data Docket: jobless claims, existing home sales conditions and a few more …

  • Philadelphia Fed business outlook, March (-1.3 expected, 5.2 previously); Initial jobless claims, week ending March 16 (215,000 expected, 209,000 previously); S&P US manufacturing PMI, March (51.8 expected, 52.2 previously); S&P Global US services PMI, March (52.0 expected, 52.3 previously); S&P US composite PMI, March (52.5 previously); Leading index, February (-0.2% expected, -0.4% previously); Existing home sales, February, month-over-month (-1.6% expected, 3.1% previously)

 

Wednesday’s night RegMed Investors (RMi) Closing Bell: “as sector cell and gene therapy sector accelerated after a down opening following the Fed’s Rorschach test. What I heard in the message from Fed chief Powell, go slow, go further; not a dollar or a % to tell investors a level for an easy landing.” … https://www.regmedinvestors.com/articles/13382

 

Q1/24: march – 6 positive and 8 negative closes

  • February – 1 market holiday, 11 positive and 9 negative closes
  • January: 2 holidays, 11 negative and 8 positive closes

 

Companies in my headlights – It’s your decision; I provide ideas and context:

I post about “indication intelligence” devoting my time to collection and analysis of information to assist investors with insight into sector vulnerabilities and strengths. A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

 

Suddenly, I am passing on forecasting the daily indications – the aftermarket seemed unfocused, the as the pre-open waits for the all-clear alarm, …  it is still a mix of ups, downs, flats and just unknowns

 

The BOTTOM LINE: My mission is to provide clear, actionable guidance on a regular basis to help investors and traders navigate the uncertain and often irrational financial markets.

  • Indexes are poised to build on a record-setting rally on Thursday as relieved investors continued to celebrate the Fed's signals it will delay but not slow rate cuts.

 

I put hours of effort into creating a daily dose of reality to reporting, while leveraging my 40 years of experience analyzing the key market-moving events and distill that into a cogent outlook.

And on the previous point (indexes are poised …), I am conflicted as to mentioned yesterday …  The use of the Rorschach test, which is a projective psychological test in which subjects' perceptions of inkblots are recorded and then analyzed using psychological interpretation, complex algorithms, or both.

  • The Rorschach can be thought of as a psychometric examination of pareidolia, the active pattern of perceiving objects, shapes, or scenery as meaningful things to the observer's experience, the most common being faces or other pattern of forms that are not present at the time of the observation.

 

There is ALWAYS a however, the cell and gene therapy sector is DUE a rebound EVEN if it is due to algorithms and electronic trading RECOGNIZING risk and the oversold!!

I STILL reiterate, “Don't chase the cell and gene therapy sector.” Short and non-sweet: SELL into STRENGTH – accumulate some “powder” i.e., cash!

 

The remainder of the month’s trading sessions will be critical as the RegMed sector continues earnings’ in LPS (loss-per-share) season, estimates and consensus which set market reaction and will report “runways” and those whose cash positions render their future questionable.

27 (of 35 covered companies) have reported …8 are left to release earnings of my covered group.

 

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”
  • The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.